Banchereau, Jacques <br/><br/>
Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.  [electronic resource] 

 -  Journal of immunotherapy (Hagerstown, Md. : 1997)   
 - 505-16 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1524-9557 
<br/><br/><label>Standard No.: </label>10.1097/01.cji.0000171292.79663.cb  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antigens, CD34--biosynthesis<br/>Antigens, Neoplasm--biosynthesis<br/>Cancer Vaccines<br/>Cell Proliferation<br/>Dendritic Cells--cytology<br/>Disease Progression<br/>Disease-Free Survival<br/>Enzyme-Linked Immunosorbent Assay<br/>HLA-A Antigens--biosynthesis<br/>HLA-A2 Antigen<br/>Humans<br/>Immunotherapy, Adoptive--methods<br/>Influenza A virus--chemistry<br/>Interferon Type I--therapeutic use<br/>Interferon-alpha--metabolism<br/>Interferon-gamma--metabolism<br/>MART-1 Antigen<br/>Melanoma--immunology<br/>Membrane Glycoproteins--biosynthesis<br/>Middle Aged<br/>Monophenol Monooxygenase--biosynthesis<br/>Neoplasm Proteins--biosynthesis<br/>Peptide Fragments--chemistry<br/>Peptides--therapeutic use<br/>Stem Cells--cytology<br/>Time Factors<br/>Treatment Outcome<br/>Viral Matrix Proteins--chemistry<br/>gp100 Melanoma Antigen